CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
2.760
-0.010 (-0.36%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma.
The company is based in La Jolla, California.
CalciMedica, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | A. Leheny |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
| Phone | 858-952-5500 |
| Website | calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
| Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
| Michael J. Dunn M.B.A., MBA | President and Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| John M. Dunn J.D. | General Counsel |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Raven D. Jaeger M.S. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 13, 2024 | SCHEDULE 13G | Filing |
| Nov 26, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 8-K | Current Report |